Posted by Michael Wonder on 25 Apr 2017
EMA publishes withdrawal assessment report for Zioxtenzo
25 April 2017 - On 18 January 2017, Sandoz officially notified the CHMP that it wishes to withdraw its application for a marketing authorisation for Zioxtenzo, intended for treating neutropenia in patients taking cancer treatments.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it would not be able to provide the additional data required by the CHMP within the timeframe allowed for the procedure.
